Garde Capital Inc. Purchases 335 Shares of Novo Nordisk A/S $NVO

Garde Capital Inc. increased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 39.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,185 shares of the company’s stock after buying an additional 335 shares during the period. Garde Capital Inc.’s holdings in Novo Nordisk A/S were worth $82,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Copeland Capital Management LLC increased its stake in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after purchasing an additional 255 shares in the last quarter. North Capital Inc. bought a new stake in Novo Nordisk A/S in the first quarter valued at $27,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at $29,000. Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S in the first quarter valued at $30,000. Finally, Disciplina Capital Management LLC increased its position in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 297 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Barclays reissued an “equal weight” rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Zacks Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 20th. Finally, Dbs Bank raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $81.00.

Novo Nordisk A/S Stock Up 1.2%

Novo Nordisk A/S stock opened at $54.94 on Friday. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $138.22. The stock has a market cap of $245.31 billion, a PE ratio of 15.09, a price-to-earnings-growth ratio of 2.06 and a beta of 0.66. The firm’s 50-day simple moving average is $57.96 and its 200 day simple moving average is $66.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to analysts’ expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S’s payout ratio is presently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.